Literature DB >> 489492

Blood levels of rifampicin, desacetylrifampicin and isoniazid during combined therapy.

R P Mouton, H Mattie, K Swart, J Kreukniet, J de Wael.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 489492     DOI： 10.1093/jac/5.4.447

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  7 in total

1.  Pharmacokinetics of oral and intravenous rifampicin during chronic administration.

Authors:  U Loos; E Musch; J C Jensen; G Mikus; H K Schwabe; M Eichelbaum
Journal:  Klin Wochenschr       Date:  1985-12-02

2.  Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.

Authors:  S Thee; J A Seddon; P R Donald; H I Seifart; C J Werely; A C Hesseling; B Rosenkranz; S Roll; K Magdorf; H S Schaaf
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

3.  Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide.

Authors:  C A Peloquin; G S Jaresko; C L Yong; A C Keung; A E Bulpitt; R W Jelliffe
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

4.  Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.

Authors:  Rovina Ruslami; Hanneke M J Nijland; Bachti Alisjahbana; Ida Parwati; Reinout van Crevel; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

5.  Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis.

Authors:  M W Teunissen; W Bakker; J E Meerburg-Van der Torren; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics of the antituberculosis drugs.

Authors:  M R Holdiness
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

7.  Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction.

Authors:  Maxwell T Chirehwa; Roxana Rustomjee; Thuli Mthiyane; Philip Onyebujoh; Peter Smith; Helen McIlleron; Paolo Denti
Journal:  Antimicrob Agents Chemother       Date:  2015-11-09       Impact factor: 5.191
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.